Junior Resident, Department of Prosthodontics, Faculty of Dental sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Junior Resident, Department of Prosthodontics, Faculty of Dental sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
J Prosthet Dent. 2022 May;127(5):709-715. doi: 10.1016/j.prosdent.2020.11.028. Epub 2021 Jan 15.
Various factors are responsible for sleep bruxism; however, whether the dopaminergic agonist group of drugs is effective in the treatment of sleep bruxism is unclear.
The purpose of this systematic review was to evaluate the effect of the dopaminergic agonist group of drugs in controlling sleep bruxism in comparison with no treatment or placebo-controlled treatment.
Two electronic databases, PubMed and Cochrane Central, were searched by using the keywords bruxism, sleep bruxism, dopamine, and dopamine agonist. After screening titles and abstracts, only those articles which met predefined inclusion criteria were selected for full-text assessment. Clinical trials using the dopaminergic agonist group of drugs as a treatment approach to sleep bruxism were included.
The literature search yielded a total of 64 articles from the 2 electronic databases (PubMed, 53; Cochrane Central, 11). After removal of the duplicates (n=8), the initial screening of titles and abstracts was performed by 2 independent reviewers, removing 46 articles. A total of 10 articles were selected for full-text reading, and 4 studies were included for qualitative analysis.
Levodopa (L-DOPA) and Bromocriptine showed decrease in root mean square value in electromyography per bruxism burst (P<.001) and 20% to 30% reduction of bruxism episodes during sleep in 2 different studies. However, treatment with bromocriptine led to conflicting result in another study in terms of frequency of bruxism episodes and amplitude of muscle contractions in electromyography (EMG). Bruxism bursts and episodes were also not significantly improved with another dopaminergic agonist group of drugs, Pramipexole (P>.001). Based on the limited evidence and conflicting results, significant conclusions cannot be generated, and further studies are required.
各种因素都与睡眠磨牙症有关；然而，多巴胺激动剂类药物是否对治疗睡眠磨牙症有效尚不清楚。
本系统评价的目的是评估与不治疗或安慰剂对照治疗相比，多巴胺激动剂类药物在控制睡眠磨牙症方面的效果。
通过使用关键词“磨牙症”“睡眠磨牙症”“多巴胺”和“多巴胺激动剂”，在两个电子数据库 PubMed 和 Cochrane Central 中进行搜索。筛选标题和摘要后，仅选择符合预先设定纳入标准的文章进行全文评估。纳入使用多巴胺激动剂类药物作为治疗睡眠磨牙症方法的临床试验。
从 2 个电子数据库（PubMed，53 篇；Cochrane Central，11 篇）共检索到 64 篇文章。去除重复项（n=8）后，由 2 位独立评审员进行标题和摘要的初始筛选，排除 46 篇文章。共选择 10 篇文章进行全文阅读，4 项研究进行定性分析。
左旋多巴（L-DOPA）和溴麦角环肽在 2 项不同的研究中显示，磨牙爆发的均方根值（P<.001）和睡眠中磨牙发作的 20%至 30%减少。然而，在另一项研究中，溴麦角环肽治疗导致磨牙发作频率和肌电图（EMG）中肌肉收缩幅度的结果相互矛盾。另一种多巴胺激动剂类药物普拉克索也未显著改善磨牙爆发和发作（P>.001）。基于有限的证据和相互矛盾的结果，无法得出明确的结论，需要进一步研究。
